Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of niraparib and pimitespib in solid tumors
jRCT2031220179Phase 1Active, not recruiting
- Sponsor
- Takeda
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of niraparib and pimitespib in Nonhematologic neoplasms, breast cancer, ovarian cancer and 4 more (3 arms), sponsored by Takeda. Primary endpoint: Incidence of dose-limiting toxicities. Started Sep 2022; status: active, not recruiting.
02
Drugs
niraparibpimitespib
03
Conditions
Nonhematologic neoplasmsbreast cancerovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2031220179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220179.